Acadia Pharmaceuticals CFO Executes Stock Sale Following RSU Vesting
Mark C. Schneyer, the Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals Inc (NASDAQ: ACAD), has completed a sale of company common stock totaling $76,395. The transaction occurred following the vesting of restricted stock units (RSUs) and was executed as a mandatory action to manage tax obligations. This movement follow…